Paper Details

  1. Home
  2. Paper Details

[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].

Author: CaoJun-jie, ChenDong, ChenLie-guang, DuXiao-hong, FanZheng, LiShuang-yue, LinLi, LiuXu-hui, MaJun-xia, PeiRen-zhi, ShaKe-ya, ShiXiao-wei, TangShan-hao, WuJing-yi, YePei-pei, ZhangBi-bo, ZhangPei-sheng, ZhuangXian-xu

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Homoharringtonine in combination with all-trans retinoic acid and arsenic trioxide was effective for newly diagnosed acute promyelocytic leukemia patients. It had a better efficacy, a higher long-term survival rate, and a lower cost compared to the standard idarubicin regimen.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To study the clinical outcome, adverse effect and treatment cost of homoharringtonine (HHT) in combination with all-trans retinoic acid (ATRA) and arsenic trioxide (AS2O3) for newly diagnosed with patients acute promyelocytic leukemia (APL). METHODS: Clinical data of treatment of newly d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23611222

データ提供：米国国立医学図書館（NLM）

Treating Acute Promyelocytic Leukemia: A Promising New Combination Therapy

The field of hematology often seeks innovative treatments for complex diseases, with acute promyelocytic leukemia (APL) posing a significant challenge. This study investigates the efficacy of a combination therapy involving homoharringtonine (HHT), all-trans retinoic acid (ATRA), and arsenic trioxide (AS2O3) in treating newly diagnosed APL. The study aimed to assess the clinical outcome, adverse effects, and cost-effectiveness of this regimen compared to a standard treatment approach.

A New Dawn for APL Treatment: A Promising Combination

The study findings suggest that the combination therapy of HHT, ATRA, and AS2O3 is a promising treatment option for newly diagnosed APL. The study demonstrates the effectiveness of this regimen, with a high complete remission rate and favorable long-term survival outcomes. This research holds great promise for improving the treatment of APL and offers a valuable alternative to existing therapies.

Living with APL: Navigating Treatment Options

If you are diagnosed with APL, it's essential to consult with a hematologist to discuss the most appropriate treatment plan. Understanding the different treatment options available and their potential benefits and risks can empower you to make informed decisions about your health. By working closely with your doctor, you can navigate the complexities of APL treatment and receive the best possible care.

Dr.Camel's Conclusion

Imagine a desert oasis where patients with APL can find refuge from the harsh realities of this disease. This research unveils a new path towards healing, offering a combination therapy that holds great promise for treating APL. It's like discovering a hidden spring within the desert, offering a refreshing alternative to traditional treatments and providing hope for a healthier future for those battling this disease.

Date :
  1. Date Completed 2013-11-07
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

23611222

DOI: Digital Object Identifier

23611222

Related Literature

Article Analysis
・Side Effects of idarubicin
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.